Estados financieros detallados de Inhibrx Biosciences Inc. (INBX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Inhibrx Biosciences Inc. registró ingresos de $1.3M en el último ejercicio fiscal, con un CAGR de 5 años del -36.7%.
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $101.77, INBX presenta beneficios negativos (P/E no significativo) y un ROE del 18.94%. La capitalización bursátil es de $1.5B.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $6.7M | $8.4M | $8.6M | $9.1M | $12.8M | $7.1M | $2.2M | $1.8M | $200000 | $1.3M |
| Coste de Ventas | $17.0M | $25.5M | $33.5M | $47.9M | 0 | $2.7M | $110.2M | $1.2M | $2.3M | $2.5M |
| Beneficio Bruto | -$10.3M | -$17.1M | -$24.9M | -$38.8M | 0 | $4.4M | -$108.0M | $609000 | -$2.1M | -$1.2M |
| I+D | $17.0M | $25.5M | $33.5M | $47.9M | $73.5M | $71.4M | $110.2M | $190.6M | $203.7M | $113.0M |
| Generales y Administrativos | $1.6M | $2.6M | $4.7M | $9.0M | $6.8M | $9.7M | $21.1M | $29.4M | $127.9M | $23.3M |
| Gastos Operativos | $18.6M | $27.7M | $4.6M | $10.1M | $80.3M | $81.1M | $21.1M | $219.8M | $329.4M | $133.8M |
| Beneficio Operativo | -$12.1M | -$19.7M | -$29.5M | -$41.0M | -$67.4M | -$76.7M | -$129.1M | -$219.2M | -$331.4M | -$135.0M |
| EBITDA | -$11.9M | -$19.3M | -$28.8M | -$39.8M | -$66.4M | -$76.5M | -$125.8M | -$206.7M | $1.70B | -$125.4M |
| Gastos por Intereses | 0 | $2.1M | $1.5M | $5.7M | $10.8M | $5.2M | $16.1M | $31.8M | $13.5M | $12.2M |
| Beneficio Antes de Impuestos | -$12.9M | -$21.8M | -$30.9M | -$50.5M | -$75.6M | -$81.8M | -$145.2M | -$239.7M | $1.69B | -$140.1M |
| Impuestos | -$4.6M | $250000 | $96000 | $898000 | $3000 | $2000 | $3000 | $3000 | $2000 | $2000 |
| Beneficio Neto | -$8.3M | -$19.4M | -$31.2M | -$51.4M | -$76.1M | -$81.8M | -$145.2M | -$241.4M | $1.69B | -$140.1M |
| BPA | $-0.23 | $-0.68 | $-1.15 | $-1.41 | $0.00 | $-2.15 | $-3.62 | $-5.12 | $116.58 | $-9.04 |
| BPA Diluido | $-0.23 | $-0.68 | $-1.15 | $-1.41 | $0.00 | $-2.15 | $-3.62 | $-5.12 | $116.58 | $-9.04 |
| Acciones en Circulación (Diluidas) | $36.6M | $28.8M | $27.1M | $36.6M | $25.3M | $38.0M | $40.1M | $47.1M | $14.5M | $15.5M |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $20.0M | $13.5M | $2.1M | $11.5M | $128.7M | $131.3M | $273.9M | $277.9M | $152.6M | $124.2M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | $696000 | $690000 | $438000 | $615000 | $878000 | $257000 | $778000 | $420000 | $177000 |
| Inventario | 0 | $999000 | $2.3M | $3.2M | -$129.3M | -$878000 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $20.4M | $15.4M | $5.7M | $15.6M | $132.2M | $139.1M | $280.5M | $295.4M | $160.4M | $132.8M |
| Inmovilizado Material | $864000 | $1.8M | $2.6M | $10.7M | $11.3M | $9.5M | $7.2M | $9.4M | $13.5M | $9.3M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $21.3M | $17.2M | $10.0M | $26.5M | $143.7M | $150.4M | $290.9M | $307.9M | $180.8M | $146.5M |
| Cuentas por Pagar | $167000 | $775000 | $6.5M | $3.1M | $13.5M | $9.1M | $8.3M | $11.0M | $9.2M | $5.9M |
| Deuda a Corto | $4.3M | $5.2M | $5.9M | $4.7M | $1.5M | $1.7M | $1.9M | 0 | $1.6M | $2.3M |
| Pasivos Corrientes | $5.3M | $8.9M | $16.2M | $20.6M | $31.4M | $22.5M | $27.6M | $56.3M | $40.7M | $33.8M |
| Deuda a Largo | $14.7M | $9.5M | $3.6M | $37.1M | $36.0M | $70.5M | $202.1M | $207.0M | 0 | $100.6M |
| Pasivos Totales | $20.0M | $39.7M | $67.6M | $120.1M | $68.3M | $98.1M | $232.8M | $264.4M | $47.2M | $138.5M |
| Reservas | -$9.2M | -$28.8M | -$17.9M | -$69.3M | -$145.4M | -$227.1M | -$372.4M | -$613.7M | -$106.1M | -$246.2M |
| Patrimonio Neto | -$9.2M | -$28.8M | -$57.6M | -$93.6M | $75.5M | $52.4M | $58.1M | $43.5M | $133.6M | $8.0M |
| Deuda Total | $18.9M | $14.7M | $9.5M | $41.7M | $37.5M | $72.1M | $207.1M | $210.1M | $8.0M | $107.0M |
| Deuda Neta | -$1.1M | $1.2M | $7.4M | $30.2M | -$91.2M | -$59.2M | -$66.8M | -$67.8M | -$144.5M | -$17.2M |
| Capital Circulante | $15.1M | $6.5M | -$10.5M | -$5.0M | $100.8M | $116.7M | $252.9M | $239.0M | $119.7M | $99.0M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$8.3M | -$22.1M | -$31.0M | -$51.4M | -$76.1M | -$81.8M | -$145.2M | -$239.7M | $1.69B | -$140.1M |
| Amortizaciones | $253000 | $399000 | $676000 | $1.2M | $1.0M | $1.2M | $1.2M | $1.2M | $2.3M | $2.5M |
| Compensación en Acciones | $552000 | $1.2M | $2.5M | $4.0M | $5.0M | $15.0M | $20.4M | $24.8M | $58.5M | $11.1M |
| Cambio en Capital Circulante | -$6.3M | $999000 | $4.2M | $3.5M | $12.7M | -$17.5M | $3.2M | $15.3M | $52.1M | -$7.6M |
| Flujo de Caja Operativo | -$18.1M | -$18.8M | -$23.1M | -$32.1M | -$48.0M | -$80.3M | -$115.3M | -$193.3M | -$194.4M | -$129.8M |
| Inversiones (CapEx) | -$215000 | -$1.3M | -$1.4M | -$1.8M | -$1.4M | -$864000 | -$686000 | -$4.6M | -$2.6M | -$31000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | $55000 | 0 | 0 | 0 | $3000 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | -$340000 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | -$1.4M | -$828000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$18.3M | -$20.1M | -$24.5M | -$33.9M | -$49.3M | -$81.2M | -$116.0M | -$197.9M | -$197.0M | -$129.8M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +25.9% | +2.4% | +5.8% | +40.9% | -44.4% | -69.2% | -17.9% | -88.9% | +550.0% | |
| Crecimiento Beneficio Neto (anual) | -135.1% | -60.3% | -64.9% | -48.1% | -7.4% | -77.6% | -66.2% | +799.2% | -108.3% | |
| Crecimiento BPA (anual) | -195.7% | -69.1% | -22.6% | +100.0% | -68.4% | -41.4% | +2377.0% | -107.8% | ||
| Cambio en Acciones (anual) | -21.2% | -5.9% | +35.0% | -30.9% | +50.5% | +5.5% | +17.5% | -69.3% | +7.0% | |
| Crecimiento FCF (anual) | -9.7% | -22.0% | -38.2% | -45.6% | -64.6% | -42.9% | -70.6% | +0.5% | +34.1% | |
| Margen Bruto | -154.9% | -204.0% | -289.2% | -426.9% | 0.0% | 62.3% | -4926.7% | 33.8% | -1042.5% | -91.0% |
| Margen Operativo | -182.2% | -235.1% | -343.4% | -450.4% | -526.6% | -1076.1% | -5890.4% | -12178.9% | -165724.0% | -10386.5% |
| Margen EBITDA | -178.4% | -230.1% | -334.7% | -437.6% | -518.6% | -1074.4% | -5739.8% | -11482.9% | 851675.0% | -9644.2% |
| Margen Neto | -124.0% | -231.7% | -362.6% | -565.3% | -594.3% | -1147.6% | -6625.3% | -13408.9% | 843786.0% | -10773.5% |
| Margen FCF | -274.8% | -239.4% | -285.3% | -372.7% | -385.2% | -1139.5% | -5291.4% | -10994.6% | -98503.0% | -9986.5% |
| Tasa Impositiva Efectiva | 35.8% | -1.1% | -0.3% | -1.8% | -0.0% | -0.0% | -0.0% | -0.0% | 0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.50 | $-0.70 | $-0.91 | $-0.93 | $-1.95 | $-2.14 | $-2.89 | $-4.20 | $-13.61 | $-8.38 |
| Dividendo por Acción | $0.00 | $0.05 | $0.03 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $36.6M | $28.8M | $27.1M | $36.6M | $25.3M | $38.0M | $40.1M | $47.1M | $14.5M | $15.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | 1893.60% |
| Rentabilidad sobre capital invertido | -99.35% |
| Rentabilidad sobre activos | -89.60% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | -0.10 |
| Ratio corriente | 5.07 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -89.70 | -30.34 | -17.94 | -14.63 | -10.94 | -20.31 | -6.81 | -7.42 | 0.13 | -8.74 |
| P/VC | -81.55 | -20.64 | -9.69 | -8.06 | 11.04 | 31.69 | 17.02 | 41.17 | 1.67 | 153.07 |
| P/V | 113.11 | 70.78 | 64.99 | 82.93 | 65.03 | 232.97 | 450.85 | 994.97 | 1114.64 | 941.13 |
| Margen Bruto | -154.9% | -204.0% | -289.2% | -426.9% | 0.0% | 62.3% | -4926.7% | 33.8% | -1042.5% | -91.0% |
| Margen Operativo | -182.2% | -235.1% | -343.4% | -450.4% | -526.6% | -1076.1% | -5890.4% | -12178.9% | -165724.0% | -10386.5% |
| Margen Neto | -124.0% | -231.7% | -362.6% | -565.3% | -594.3% | -1147.6% | -6625.3% | -13408.9% | 843786.0% | -10773.5% |
Empresas relacionadas: AMLX · ATAI · CVAC · ELVN · IMTX · NKTR · ORIC
Explorar sector: Healthcare · Biotechnology
Más secciones de INBX: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones